Related Experiment Video

Updated: Aug 20, 2026

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
06:15

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

Published on: June 14, 2015

A marriage of enhancement: fibrinolysis and conjunctive therapy

Robert C Welsh1, Paul W Armstrong

  • 1The University of Alberta, Department of Medicine, Division of Cardiology, Edmonton, AB T6G 2H7 Canada.

Thrombosis and Haemostasis
|December 8, 2004
PubMed

Insights

Pharmacologic reperfusion using fibrinolytics and adjunctive therapies like anticoagulants and antiplatelets improves outcomes for ST-elevation myocardial infarction patients. Novel agents are crucial for comprehensive treatment and enhanced survival.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acute ST-segment elevation myocardial infarction (STEMI) requires prompt reperfusion.
  • Fibrinolytic monotherapy alone is insufficient for optimal patient outcomes.

Purpose of the Study:

  • To review pharmacologic reperfusion strategies for STEMI.
  • To discuss the role of various antithrombotic and antiplatelet agents.

Main Methods:

  • Review of current literature on pharmacologic reperfusion in STEMI.
  • Discussion of unfractionated heparin, enoxaparin, direct thrombin inhibitors, aspirin, and glycoprotein IIb/IIIa inhibitors.

Main Results:

  • Combination therapy with fibrinolytics and antiplatelet/antithrombotic agents is necessary.
  • Glycoprotein IIb/IIIa inhibitors show promise but have risks in the elderly.
  • Facilitated percutaneous coronary intervention is a potential future strategy.

Conclusions:

  • Optimal STEMI reperfusion requires a multifaceted pharmacologic approach.
  • Future research should focus on novel antiplatelet, antithrombin, and anti-inflammatory agents.

More Related Videos

The Combination of Mechanically Isolated Stromal Vascular Fraction and Fibrin Hydrogel: A Processing Protocol05:30

The Combination of Mechanically Isolated Stromal Vascular Fraction and Fibrin Hydrogel: A Processing Protocol

Published on: November 17, 2023

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model06:16

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model

Published on: April 19, 2024

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Fibril-associated Collagen01:11

Fibril-associated Collagen

Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...